Beacon Pharmaceuticals PLC's latest marketcap:
As of 07/05/2025, Beacon Pharmaceuticals PLC's market capitalization has reached $197.23 M. According to our data, Beacon Pharmaceuticals PLC is the 20312th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 197.23 M |
| Revenue (ttm) | 93.97 M |
| Net Income (ttm) | 4.63 M |
| Shares Out | 231 M |
| EPS (ttm) | 0.02 |
| Forward PE | 0.00 |
| Ex-Dividend Date | 10/28/2024 |
| Earnings Date | 11/27/2025 |
Beacon Pharmaceuticals PLC's yearly market capitalization.
| Date | Market Cap(BDT) | Change (%) | Global Rank |
|---|---|---|---|
| 07/05/2025 | 197.23 M | -22.59% | 20312 |
| 12/30/2024 | 31.39 B | -44.53% | 17350 |
| 12/28/2023 | 56.6 B | -14.34% | 12803 |
| 12/29/2022 | 66.07 B | 17.5% | 10737 |
| 12/30/2021 | 56.23 B | 210.46% | 11653 |
| 12/30/2020 | 18.11 B | 74.61% | 16433 |
| 12/30/2019 | 10.37 B | 177.16% | 17114 |
| 12/27/2018 | 3.74 B | -23.94% | 21580 |
| 12/28/2017 | 4.92 B | -3.18% | 20673 |
| 12/29/2016 | 5.08 B | 46.67% | 18128 |
Company Profile
About Beacon Pharmaceuticals PLC
Beacon Pharmaceuticals PLC is a leading pharmaceutical company specializing in the production and promotion of high-quality healthcare products. Established in 2001 and headquartered in Dhaka, Bangladesh, the company operates both domestically and internationally.
Product Portfolio
The company offers a diverse range of pharmaceutical solutions, including:
- Finished Formulations – Comprehensive drug formulations for various therapeutic needs.
- Lifesaving Intravenous Fluids – Critical care solutions for medical emergencies.
- Active Pharmaceutical Ingredients (APIs) – High-quality raw materials for drug manufacturing.
- Bio-Tech & Genetic Engineering Products – Innovative treatments leveraging advanced biotechnology.
Therapeutic Categories
Beacon Pharmaceuticals serves multiple medical fields, including:
- Oncology & Hematology
- Hepatology & Nephrology
- Antibiotics & Analgesics
- Anti-Diabetics & Respiratory Care
- Cardiovascular & Dermatology
- Gastrointestinal & Infectious Diseases
- Immunology & Rheumatology
- Pediatrics & Nutritional Supplements
Contract & Toll Manufacturing
In addition to its branded products, the company provides contract and toll manufacturing services to support pharmaceutical production needs.
Brand Portfolio
Beacon Pharmaceuticals markets its products under well-known brand names such as:
- Pemro, Nivomab, Xelpac Premium
- Docexan, Xaloplat Aqua, Gemoxen Aqua
- ETP, FXR, Renesis, Mezest
- Eposis, Tirza, Xelmet, Xerova
- Sinjard, Ovocal, Haxinor, Tetrazin
- Lubilux, Paloxi, Olonex, Bukof
Frequently Asked Questions
-
What is Beacon Pharmaceuticals PLC's (DSE-BEACONPHAR) current market cap?As of 07/05/2025, Beacon Pharmaceuticals PLC (including the parent company, if applicable) has an estimated market capitalization of $197.23 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Beacon Pharmaceuticals PLC (DSE-BEACONPHAR) rank globally by market cap?Beacon Pharmaceuticals PLC global market capitalization ranking is approximately 20312 as of 07/05/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.